胃食管癌22项新辅助试验中总生存期的替代终点
该研究纳入22项随机试验共4749例接受新辅助放化疗或化疗的胃或食管癌患者,评估无病生存期(DFS)和病理完全缓解(pCR)与总生存期(OS)的替代关系。试验水平上,DFS和pCR的治疗效应与OS治疗效应不相关(R²分别为0.27和0.17)。结论认为DFS和pCR不应作为胃食管癌新辅助治疗患者的替代终点,OS仍应作为未来随机临床试验比较治疗的主要终点。
要点
- 在22项新辅助试验共4749例胃食管癌患者中,DFS和pCR的治疗效应与OS治疗效应不相关。
- 试验水平替代性分析显示,DFS的R²=0.27,pCR的R²=0.17。
- DFS的替代性在胃癌中良好,在食管癌中较差;作者认为DFS和pCR不应作为替代终点。
核心结论
- DFS和pCR与OS不相关,不应作为胃食管癌新辅助治疗患者的替代终点。
- OS仍应作为未来随机临床试验比较治疗的主要终点。
研究设计与样本
- 研究纳入22项随机试验,共4749例接受新辅助放化疗或化疗的胃或食管癌患者。
- 采用加权线性回归分析评估替代性,相关性以决定系数R²评价,并按意向治疗人群患者数加权。
- 通过终点与OS的相关性(个体水平替代性)以及治疗对终点的效应之间的相关性(试验水平替代性)评估DFS和pCR对OS的替代性。
主要发现
- 试验水平上,DFS的治疗效应与OS的治疗效应不相关(R²=0.27)。
- 试验水平上,pCR的治疗效应与OS的治疗效应不相关(R²=0.17)。
- 亚组分析中,DFS的替代性不随组织学类型或治疗方式变化,但在胃癌中良好,在食管癌中较差。
临床怎么用
- 作者认为DFS和pCR不应作为胃食管癌新辅助治疗患者的替代终点。
- 作者认为OS仍应作为未来随机临床试验比较治疗的主要终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The surrogacy between disease-free survival (DFS) and overall survival (OS) has been evaluated in patients with gastric cancer who received adjuvant chemotherapy. Similar analyses in patients who have undergone neoadjuvant chemoradiotherapy (CTRT) or chemotherapy (CT) for gastro-oesophageal (GE) cancer have not yet been performed. METHODS: We evaluated the correlation between DFS and pathologic complete response (pCR) with OS in patients with GE carcinomas enrolled in randomised studies. A weighted linear regression analysis was used to evaluate surrogacy. Correlations were evaluated by squared correlation R2. Surrogacy of DFS and pCR with OS was assessed through the correlation between end-points and OS (individual-level surrogacy), and between the treatment effects on the end-points (trial-level surrogacy). Correlations were weighted by the number of patients in the intent-to-treat population. RESULTS: Twenty-two trials were included for a total of 4749 patients that received CTRT or CT for gastric or oesophageal cancers. Treatment effect on surrogates did not correlate with treatment effect on OS (R2 = 0.27, and R2 = 0.17, for DFS and pCR) at the trial level. In subgroup analysis surrogacy of DFS did not vary according to histology or treatment modality but was good in gastric cancer and poor in oesophageal cancers. CONCLUSIONS: DFS and pCR did not correlate with OS, and should not be used as surrogate end-points in patients with GE cancer who have undergone neoadjuvant therapy. OS should still represent the primary end-point to compare treatments in future randomised clinical trials.
引用
- Petrelli F, Tomasello G, Barni S, et al. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. Eur J Cancer. 2017. PMID: 28262586. doi:10.1016/j.ejca.2017.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。